“重基础 求创新—推动新时代北大药学高质量发展” 药学院召开新学期发展战略研讨会.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 3, p. 236
- Publication type:
- Article
Works matching IS 10031057 AND DT 2023 AND VI 32 AND IP 3
Results: 10
1
2
曾克武/屠鹏飞团队研究成果入选 “2022 年度中医药十大学术进展”.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 3, p. 234
- Publication type:
- Article
3
清华大学药学院刘刚教授主编的《药物化学与药物研发案例》正式出版发行.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 3, p. 231
- Publication type:
- Article
4
The introduction of nitrosamine impurities in medicinal products.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 3, p. 223, doi. 10.5246/jcps.2023.03.020
- By:
- Publication type:
- Article
5
The preparation and characterization of sustained-release solid dispersion of resveratrol by hot-melt extrusion technology.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 3, p. 165, doi. 10.5246/jcps.2023.03.014
- By:
- Publication type:
- Article
6
The effects of midazolam combined with dezocine on laparoscopic appendectomy.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 3, p. 207, doi. 10.5246/jcps.2023.03.018
- By:
- Publication type:
- Article
7
Effect of vitamin D supplementation on metabolic syndrome: a retrospective study.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 3, p. 200, doi. 10.5246/jcps.2023.03.017
- By:
- Publication type:
- Article
8
Warfarin affects the proliferation and apoptosis of lung cancer cells by regulating the Gas6/Axl/PI3K/Akt/NF-κB pathway.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 3, p. 190, doi. 10.5246/jcps.2023.03.016
- By:
- Publication type:
- Article
9
A study of irritable bowel syndrome model construction based on combined factor stimulation.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 3, p. 180, doi. 10.5246/jcps.2023.03.015
- By:
- Publication type:
- Article
10
Evidence-based pharmacoeconomic evaluation of palbociclib in combination with letrozole versus docetaxel in combination with epirubicin in the first-line treatment of advanced breast cancer with epirubicin.
- Published in:
- Journal of Chinese Pharmaceutical Sciences, 2023, v. 32, n. 3, p. 214, doi. 10.5246/jcps.2023.03.019
- By:
- Publication type:
- Article